Novacyt Initiates Consultation on Significant Workforce Reduction
Novacyt announces the initiation of a consultation process that could lead to a workforce reduction of up to 40% across the Group. This reorganization is part of an effort to streamline operational costs following the launch of new products and the integration of the acquisition of Southern Cross Diagnostics.
Novacyt has started a consultation process regarding a potential reduction of up to 40% of its current workforce. The group had approximately 230 employees as of May 26, 2026. The outcome of this process will be communicated at a later date.
This reorganization follows the successful launch of several new products over the past 18 months and the recent acquisition of Southern Cross Diagnostics in March 2026. The group is accelerating its plans to refocus and streamline its operations and cost structure.
Estimated Cash Savings of 4 Million Pounds Sterling
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Once implemented and finalized, the restructuring is expected to generate annual savings of approximately £4 million in cash consumption, combining reductions in salary and non-salary costs. Restructuring expenses of about £1 million are expected to be incurred.
These figures are provided pending the outcome of the consultation process and are based on the assumption of a total 40% reduction in workforce.
Related
SectorÉquipements et Services Médicaux›Équipements Médicaux
Context
Period
Period: 2025
Guidance from the release
La période de restructuration et d'intégration étant désormais clôturée, et l'activité stabilisée et moins risquée, nous nous sommes engagés à générer une croissance du chiffre d'affaires.
Croissance du chiffre d'affaires conforme aux attentes du marché; croissance semestrielle confirmée; pipeline solide pour 2026 et au-delà; groupe sans dette.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
